Combined Lung Immune Prognostic Index (LIPI)-Glasgow Prognostic Score (GPS) as a Prognostic Tool in Extensive-Stage Small-Cell Lung Cancer Treated with First-Line Chemo-Immunotherapy
LIPI and GPS are strong independent prognostic markers in ES-SCLC receiving chemoimmunotherapy. While CIPS did not demonstrate independent prognostic value in multivariate analysis, its simplicity, balanced two-tier design, and use of routinely available biomarkers highlight its potential clinical utility. To our knowledge, this is the first study to assess a combined inflammatory prognostic model in this population. Prospective multicenter validation is warranted.
Authors
- Burçin Çakan Demirel (ORCID: https://orcid.org/0000-0003-0734-0692)
- Mesut Şeker (ORCID: https://orcid.org/0000-0001-9245-6790)
- Sena FİDAN (ORCID: https://orcid.org/0000-0001-8895-296X)
- Fatih SELÇUKBİRİCİK
- Özgür Açıkgöz (ORCID: https://orcid.org/0000-0003-2715-4002)
- Jamshid Hamdard (ORCID: https://orcid.org/0000-0002-5823-1704)
- Fatih Kemik (ORCID: https://orcid.org/0000-0001-6085-1921)
- Yasin Kutlu (ORCID: https://orcid.org/0000-0003-2184-634X)
- Mehmet Haluk Yücel (ORCID: https://orcid.org/0000-0001-6880-7204)
- Maral Martin Mıldanoğlu (ORCID: https://orcid.org/0000-0002-4587-0726)
- Ebru Engin Delipoyraz (ORCID: https://orcid.org/0000-0003-4979-3630)
- Harun Muglu
- Melisa Eryaşar
- Ahmet Bilici
- Hakan Özçelik
- Erdem Sünger
Institutions
- Koç University (TR)
- Istanbul Medipol University (TR)
Publication Details
- Journal
- Pharmaceuticals
- Published
- 2026-04-07
- DOI
- https://doi.org/10.3390/ph19040587
- Primary Topic
- Inflammatory Biomarkers in Disease Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00